• Nextech Founder and CEO Evan Gappelberg will present at the OTCQB Venture Virtual Investor Conference, scheduled for August 5, 2021, and later at the Jefferies Software Conference to be held September 14 to 15, 2021
• Earlier this year, Evan presented at a Virtual Investor Conference, wherein he highlighted the company’s plans, some of which it has already implemented
• Thus, during the upcoming conferences, which will bring together companies and investors, attendees can expect to learn more about Nextech, its core business, expectations, and more

Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF), one of the leaders in the rapidly growing augmented reality (“AR”) industry, recently announced that Founder and CEO Evan Gappelberg will present at two upcoming conferences geared towards bringing companies and investors together. On August 5, 2021, starting from 9.30 AM ET, Evan will present at the OTCQB Venture Virtual Investor Conference. The live and interactive online event organized by Virtual Investor Conferences (“VIC”) and beamed live on VirtualInvestorConferences.com will feature favorite venture companies traded on the OTCQB (https://ibn.fm/jACO2). A premier proprietary investor conference series, VIC provides an interactive forum for publicly traded companies to discuss their businesses and investment stories, in addition to answering questions from investors. As a live, online event under the VIC umbrella, therefore, the OTCQB Venture Virtual Investor Conference will not be an outlier. It will promote interactivity by allowing investors to ask companies questions in real-time. The organizers will also make available an archived webcast of the presentations after the event. Similarly, Evan will present and host 1×1 meetings at the annual Jefferies Software Conference scheduled for September 14 to 15, 2021. Aimed at addressing both near- and long-term investment opportunities, as well as discussing current trends in the United States and beyond, the upcoming event will bring together public and private software companies, leading executives, institutional investors, venture capitalists (“VCs”), and private equity investors. It will feature 1×1/small group meetings, company presentations, fireside chats, and panels (https://ibn.fm/hhmbi). These two presentations will come just a few months after a February 4 precursor (https://ibn.fm/HlFcV) – which was also a VIC event – during which Evan outlined Nextech’s progress up until that point and expectations for 2021, including planned product and technology launches, as well as its revenue forecast. “Before we get started with the presentation, I just want to put a little context into the presentation. In 2019, we generated $6 million in revenue. In 2020, we preannounced our revenue as $20 million, and in 2021, we are estimating $50-$60 million in revenue,” Evan began (https://ibn.fm/zHpiq). He then went on to describe “catalysts” for the company beyond revenue, which mainly revolved around expected technology launches within its AR division. These included a proprietary Ad Network and a live holoportation feature on its AirShow App. Nextech has since launched these two technologies in addition to others, such as LiveX, its digital experience platform (“DXP”) released May 12, and EdTechX, a higher education solution built on Microsoft Azure and available on the LiveX platform. If the earlier VIC presentation is anything to go by, attendees at the two upcoming conferences can expect to gain more insight into Nextech, its expectations for the future, and the progress it will have made up until then. They can also expect to learn more about AR, Nextech’s core business, present and emerging technologies that will support AR, and more. For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF

• Company executed record quarter by focusing on profitable operations, accretive acquisition of Homegrown Oregon
• Chalice posts record quarterly revenue, gross profit numbers
• Homegrown chain of five stores joined the Chalice brand earlier this year

Chalice Brands (CSE: CHAL) (OTCQB: CHALF) has released its 2021 second-quarter unaudited financial, noting highest-ever quarterly revenues, along with other promising numbers (https://ibn.fm/JETHJ). The company is a premier consumer-driven company specializing in the retail, production, processing, wholesale and distribution of cannabis. “We are immensely proud to execute another record quarter by focusing on profitable operations and the accretive acquisition of Homegrown Oregon,” stated Chalice CEO and president Jeff Yapp “The integration of Homegrown and the adoption of our vertical products within the new stores is ahead of schedule. The staff are highly engaged and motivated to be part of the Chalice family. The whole team is energized and focused on growth as we showcase our brand portfolio nationally and remain dedicated to our ‘crawl-walk-run’ strategy.” In the release, Chalice reported quarterly revenues from continuing operations of $6.8 million, a record high for the company and a 23% year-over-year increase compared to $5.5 million for the same period in 2020. Other impressive numbers for the quarter included an 82% increase in estimated gross profit. For Q2 2021, the company totaled $3.1 million, which represents a 46% gross profit margin compared to $1.7 million, or 37% gross profit margin rate in 2020. The company attributed the gross margin improvements to increased sales of vertical, in-house products manufactured by Chalice and increased third-party processing revenues. “We will seek to continue our growth both organically and through any opportunistic and accretive transactions we may be able to execute upon,” said Chalice executive chairman John Varghese. In May 2021, the company finalized its 100% ownership of SMS Ventures LLC, known as Homegrown Oregon, a chain of five retail dispensaries located in Portland, Salem and Albany, Oregon (https://ibn.fm/aIJiA). “The completion of this transaction increases our retail store footprint to 12 locations in the state of Oregon, supported by our own award-winning cultivation operations, our production facilities in Portland and our internal wholesale team covering the state,” said Yapp. “Chalice has set a target to achieve 5% market share in Oregon while we grow in other markets. Homegrown helps us progress toward that goal.” Chalice Brands is a premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, with twelve dispensaries in Portland, Oregon. The company is committed to developing a dynamic portfolio built around the recognized brands of Chalice Farms, with a focus on health and wellness. Chalice operates nationally through Fifth and Root and has operations in Oregon and California. For more information, visit the company’s website at www.ChaliceBrandsLtd.com. NOTE TO INVESTORS: The latest news and updates relating to CHALF are available in the company’s newsroom at https://ibn.fm/CHALF

• Lexaria Bioscience is a drug delivery technology developer advancing its IP for transforming existing consumer products and medications that may improve their availability and bioavailability
• The analysis of Lexaria’s DehydraTECH(TM) shows it did not create unwanted new molecular entities during the transformation process, did not inhibit the drugs’ expected antiviral functions and did increase absorption
• The DehydraTECH testing has been in conjunction with drugs used to treat SARS-CoV-2/COVID-19, HIV/AIDS and hepatitis, although the company envisions its technology becoming responsive to a much wider array of viral illnesses
• The company envisions building on its recent successes with larger studies of the DehydraTECH process in animals infected with viruses such as SARS-CoV-2/COVID-19 or HIV/AIDS and hopes to eventually form partnerships with established pharmaceutical giants

Oral drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX)provided investors an update July 22 on the success of its efforts to advance its proprietary technology toward scalable commercial use for improving the treatment of select viral illnesses. Lexaria has met three primary objectives in its investigation of antiviral drug conversion process outcomes as the antiviral drugs are processed with Lexaria’s patented DehydraTECH, according to the company’s news release (https://ibn.fm/H4wBZ). Lexaria aims to make drugs more bioavailable through DehydraTECH conversion without impairing the drugs’ essential functions. Many antiviral drugs currently available experience a decrease in bioavailability when taken orally because of poor intestinal uptake and/or significant liver biotransformation within the patients’ bodies — the company cites the anti-inflammatory drug colchicine, which has a bioavailability of about 45 percent and a narrow margin between what is regarded as safe and toxic dosing. Lexaria’s three primary objectives in testing DehydraTECH’s processing of colchicine and four other anti-inflammatories — darunavir, ebastine, efavirenz and remdesivir — were to determine if DehydraTECH processing would demonstrate evidence of increasing absorption through oral delivery, evidence that the drug compounds would continue to inhibit viruses as expected in mammalian cells, and evidence that the processing would not lead to the creation of new molecular entities (“NMEs”) requiring new regulatory approvals. The success achieved during the company’s testing paves the way for larger analysis of the DehydraTECH-processed drugs in vivo in animals infected with SARS-CoV-2/COVD-19, HIV/AIDS or other infectious disease-causing viruses, according to the company, with the ultimate aim of forming partnerships with established pharmaceutical industry drug-makers who may be interested in incorporating DehydraTECH technology with those tested drugs, or other drugs with similar characteristics. The five drugs being analyzed in conjunction with DehydraTECH processing are representative of protease inhibitors (“PIs”), reverse transcriptase inhibitors (“RTIs”) and a tubulin polymerization and microtubule inhibitor (“TPMI”) used to treat HIV, hepatitis C, hepatitis B, COVID-19 infections and cancers. Lexaria hopes to apply its discoveries to pharmaceuticals that fight other virus-triggered diseases such as shingles, influenza and viral forms of gastroenteritis, hepatitis, meningitis, and pneumonia. The company’s news release cites statistics noting that 37.7 million people are currently known to be infected with HIV and 36.3 million people have died from HIV/AIDS since the beginning of the epidemic, between 290,000 and 650,000 people die every year from virus-driven seasonal influenza, and over 189 million people have been infected by SARS-CoV-2 in the current global epidemic with more than 4 million of them killed by the illness. Vaccines have helped reduce the incidence and mortality of these viral illnesses, but effective oral delivery has the potential to increase the availability of medications where vaccines cannot be widely administered. Additionally, in each of the antiviral drug classes currently being tested, the outcomes in animals have demonstrated up to a three-fold increase in bioavailability to the bloodstream over established methods, which may ultimately prove a means of reducing the costs of administration. “We are looking at repurposing some of these drugs, being able to take an antiviral drug that traditionally could only be administered, for example, by injection. We might be able to apply it in an oral form through a pill,” Lexaria CEO Chris Bunka told Investing News Network in a June report (https://ibn.fm/OTtde). “Our delivery from oral to the bloodstream is as little as two minutes. We’re outrageously fast for oral technology,” Bunka stated. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Approximatively 75-85% of patients with confirmed cases of bladder cancer are diagnosed with non-muscle invasive (“NMIBC”)
• Imagin Medical’s innovative technology is targeting this type of bladder cancer and set to be completed in 2022
• Blue light cystoscopy helps surgeons visualize the cancerous cells that are not detected by white light, enabling an improved resection

Non-muscle-invasive bladder cancer (“NMIBC”) is a type of bladder cancer that has not infiltrated the other muscle tissues inside the bladder or spread to the lymph nodes. Approximately 75-85% of patients presenting with bladder cancer are diagnosed with NMIBC. The most common symptoms of NMIBC which may prompt initial testing is blood in the urine (https://ibn.fm/wO76R). The primary procedure used to detect bladder cancer is called a cystoscopy, which uses an endoscope and, typically, white light visualization. White light cystoscopy has been the standard for more than 90% of the procedures for decades and is beneficial in removing cancerous growths that protrude from the bladder wall. Yet, it is almost impossible to detect and resect cancerous cells that lay flat against the bladder, leaving some cells behind and causing a higher risk of recurrence. Approximately 50% of patients who have had a cystoscopy to remove NMIBC see their cancer return. Right now, approximately 724,000 people are living in fear that their bladder cancer will come back (https://ibn.fm/Ker0P). Blue Light Cystoscopy (“BLC”), used with and FDA approved imaging agent that fluoresces the cancer cells, was introduced in 2010.  Although proven to be more effective in identifying cancerous cells and reducing recurrence, blue light is still only used in approximately 10% of bladder cancer procedures due to training, cost and ease-of-use issues. To address these issues,  Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed the i/Blue Imaging System(TM), an innovative technology designed to significantly improve the way surgeons visualize cancerous cells for more accurate bladder resection. This patented technology allows for white and blue light images to be projected side-by-side simultaneously, enabling better surgical technique. The i/Blue System will attach to most endoscopes currently on the market, protecting hospitals’ investment in instruments they already own and enabling their adoption of blue light cystoscopy at a significant cost savings. Imagin Medical’s technology has entered the manufacturing stage with the company’s partner, Lighthouse Imaging, an FDA-registered and ISO 13485:2016 certified manufacturer. The i/Blue Imaging System is expected to be completed in 2022. With the i/Blue Imaging System, Imagin Medical is poised to establish a new standard in bladder cancer visualization by radically changing how cystoscopies are performed and ultimately helping improve patients’ lives and long-term outlook. Imagin Medical’s target is estimated to be a $400M portion of the global endoscopy market valued at $25.59 billion in 2019 and is expected to grow at a CAGR of 6.6 percent to reach a total estimated value of $35.23 billion by 2024 (https://ibn.fm/5jNuO). For more information, visit the company’s website at www.ImaginMedical.com. NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• The company plans to incorporate systemic environmental, social, and governance (“ESG”) factors into business planning and investment decision-making
• The initial Sustainability Accounting Standards Board (“SASB”) report has been completed, and sustainability consulting firm KERMIDA Inc. is currently organizing the data compiled by Green Hygienics
• An ESG program can significantly benefit companies in the industry, from drawing in more investors to winning new business, gaining better talent and improving media coverage
• The industrial hemp market size is expected to reach $15.26 billion by 2027 due to the rising demand for food, supplements, cosmetics, and personal care items

Green Hygienics Holdings (OTCQB: GRYN), a California-based innovative and tech-based enterprise that is focused on the high cultivation standards, processing, and manufacturing of industrial hemp for pharmaceutical-grade bioactive cannabinoids, is enhancing its corporate responsibility and sustainability goals to empower environmental progress. The company plans to incorporate systemic environmental, social, and governance (“ESG”) factors into business planning and investment decision-making. With the help of KERAMIDA Inc., a premier sustainability consulting firm, Green Hygienics is developing a Sustainability and ESG report using the Sustainability Accounting Standards Board (“SASB”) framework, maintained by the Value Reporting Foundation. Sustainability and ESG are an integral part of the Company’s value system and are committed to driving sustainability by becoming a more effective corporate citizen. Green Hygienics is the first industrial hemp company to undertake a Sustainability and ESG report. The company is getting ahead of the government’s push to require ESG metrics measurement and reporting. Investors are also pressuring companies to measure, benchmark, and report ESG metrics. These investors pay a premium on companies that develop strong ESG policies. These are the companies that are seeing better valuations and market performance. According to a Hemp Industry Daily report, companies of all sizes in the industry can realize significant benefits from developing a corporate responsibility program, including (https://ibn.fm/Oef37):

• Winning new business and increasing customer retention
• Attracting talent and maintaining an exuberant workforce
• Positive media
• Differentiation from competitors
• Saving money on energy and operating costs

ESG goals are achievable by any firm by breaking down the concept into different components:

• Environmental impact – covering everything from a company’s greenhouse gas emissions to resource depletion, nature conservation, waste, and pollution.
• Social impact – including a firm’s working conditions, employee relations, health, and safety. It also includes a firm’s interaction with local and indigenous communities.
• Governance – consisting of the structures within a company, like the board of directors, diversity, pay equity, political lobbying, tax strategy, supply chain policies, and executive pay.

ESG is the measurement of all these different aspects, benchmarking them, and reporting them. Green Hygienics is positioned to deliver a secure supply chain solution and product efficacy to a range of industry customers and leverage the strategic advantages within its own consumer brand portfolio, securing a strong position in the expanding hemp market. The size of the industrial hemp sector is expected to reach $15.26 billion by 2027, expanding at a CAGR of 15.8% over the forecast period. In North America, the market is expected to expand by a CAGR of 20.4% from 2020 to 2027 due to the rising demand for food, supplements, cosmetics, and personal care items (https://ibn.fm/RJC6f). Developing an ESG program is likely to further cement Green Hygienics’ position in the market, as well as influence positive investor interest and growth opportunities. The company has already finished its SASB Report process and is now interviewing and collecting data from utilities, while also organizing the related data for the KERMIDA Inc. team. Green Hygienics hopes to create the final ESG report in about a month. For more information, visit the company’s website at www.GreenHygienics.com. NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

• The single biggest slice of an artists’ earnings (28%) comes from touring, meaning live performances, and, with the pandemic, artists were restricted in doing live shows
• Friendable addresses this with its Fan Pass platform, allowing artists to make money from virtual events, video content views, artist contests, merchandise sales, and even ticket sales
• Friendable continues to innovate and leverage technology to address the new challenges that artists face

As of early 2020, touring, shows, and live performances accounted for much of an artists’ earnings, at 28%. This was closely followed by teaching at 22%, salaries at 19%, session playing at 10%, and then composing and songwriting at 6% (https://ibn.fm/snips).

With the growing challenges associated with live performances and shows, artists are exploring new ways to deliver the same experience to their audience and make money from it. Virtual experiences prove to be more appealing to artists given how well they have taken up different social media platforms and their websites.

So far, numerous platforms have presented a compelling value proposition for artists and how they can make money. However, very few stand out as much as Fan Pass does.

Friendable (OTC: FDBL) is a mobile technology marketing company focused on developing and identifying products, services and brand opportunities with mass market potential and scalability. Friendable has since removed the social dating app from the app stores and has pivoted its business focus to Fan Pass, the livestream artist platform. Launched July 24, 2020, the Fan Pass livestream platform has proven to be invaluable for artists and fans alike as performances shifted from the stage to the screen (https://ibn.fm/OxUL5).

At the core of Friendable’s Fan Pass platform, the company is committed to connecting fans to their favorite artist. Doing so allows the artist to make money from their art and brand. More importantly, they do this virtually and while breaking the mold of the traditional music industry.

In April 2021, Friendable announced that it would offer Non-fungible Tokens (“NFTs”), a unique addition to its product and service offering (https://ibn.fm/3aunf). Each NFT offered would represent a unique opportunity for the artist and any other parties involved to monetize and seek other opportunities with brand sponsors and retail brands.

The NFT addition allows artists to increase their value through multiple limited-edition releases dependent on availability and exclusivity. This means fans can enjoy exclusive privileges such as access to the artist or limited-edition merchandise, while the artist can make money from their art and their brand.

As of July 2021, Friendable had over 5,000 Fan Pass artist sign-ups, a massive milestone for the company (https://ibn.fm/zzsBK). Additionally, on July 24, 2021, the company submitted its Fan Pass version 2.0 Livestream artist platform to the Apple App and Google Play Stores, which shows its commitment to innovation and the use of technology to appeal more to artists. Even as these signify the company’s growth, they also show that artists appreciate the value that Friendable is offering and the opportunities it presents for their revenue and overall brand growth.

As time progresses, Friendable continues to strengthen its commitment to further innovating and building its product line, thereby bringing even more value to the audience and, most importantly, the artists. The company also continues to leverage technology to achieve this and has made incredible achievements so far. It continues to prioritize the artist as it seeks to address the new challenges they continue to face as time progresses.

For more information, visit the company’s website at www.Friendable.com.

NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

 

• Providing a holistic approach to therapeutic plant treatment by unlocking data from seed to consumption
• RYAH Group is providing needed dosing devices globally to drive innovation and deliver cutting edge plant-based medical solutions globally
• With over 200k registered users, RYAH Group is one of the largest plant-based medicine databases in the world and regularly releases and shares valuable insights collected

RYAH Group (CSE: RYAH), formerly RYAH Medtech, is leading the way forward by providing a holistic approach to therapeutic plant treatment by unlocking the data in the complete plant lifecycle (seed to consumption). Known for its high-quality information and digital health care analytics, RYAH Group is positively impacting the future treatment of patients for various medical conditions worldwide. The Company has globally expanded its reach in IoT hardware, software, and data analytics making it possible for researchers to significantly reduce variations in patient-related trials. Whether combining forces with the University of Milan to rigorously map out the behavior of cannabis strains to create accurate milligram dosing (https://ibn.fm/ksB18), providing the necessary dose-measuring devices to an oncology clinic in the UK for the largest of its kind cannabis clinical trial (https://ibn.fm/QlZ6L), or partnering with companies like Medical Kiwi to drive innovation and deliver cutting edge plant-based medical solutions in New Zealand (https://ibn.fm/35Rjh) – RYAH Group is paving the way for a better understanding and better outcomes of plant-based treatments globally. This is achieved by having multiple touch points and working with multiple players throughout the plant’s lifecycle. The Company has partnered with growers, dispensaries, clinical trials, researchers, and patients to collect seed-to-consumption data. This creates a deeper understanding of the roles of formulations and dosing in treatments. In order to collect the data, RYAH Group has created smart devices combined with artificial intelligence and an integrated platform that allow both the patient and doctor to regulate prescriptions safely and seamlessly. The HIPAA-compliant patient data is monitored by an AI platform throughout the patient’s session and formulation lifecycle providing additional data that is fed into the Cloud that continues the process. The Company’s smart devices include:

• RYAH Smart Patch – used primarily by physical therapists and cannabis-treated patients, pain relief professionals and occupational therapists for site-specific therapy to treat a variety of conditions
• RYAH Dry-herb Inhaler – measures inhalations to deliver precise and predictable results
• RYAH Pen – oral drug dispenser connected to a mobile application, allows users to track dosing and usage statistics
• RYAH MD – platform for doctors to remotely monitor and control their patients’ dosing regimen with RYAH’s suite of dose measuring products

RYAH Group uses a data-driven approach that combines dosing data, lab test information, and consumer feedback. Big data and AI are used to discover breakthroughs and better enable providers to create highly personalized dosing regimens for the end users. With over 200k registered users, RYAH Group is one of the largest plant-based medicine databases in the world and regularly releases and shares valuable insights collected. These data reports are released monthly and available to everyone at www.RYAHGroup.com/news. In the U.S., study has been limited for the last 50 years due to federal regulations. But change is on the horizon (https://ibn.fm/O1efL). Researchers in the U.S., currently restricted to federally cultivated cannabis, will soon have access to the therapeutic plants and products that end users are actually using. Cannabis research in 2022 will be conducted in a way that will benefit the consumer and lead to better medicinal products and safer recommendations. RYAH is ready and has the necessary IoT devices needed to ensure these future studies collect and analyze the data in the most effective way possible. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

• Some estimate the U.S. will run out of landfill space within 15 years
• This year’s hurricane season expected to have above average activity
• SGTM, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging, sales

This month, the world watched as Hurricane Elsa made landfall in Cuba on July 5, tore through Jacksonville, Florida days later and then proceed to wreak havoc up the East Coast and into Atlantic Canada (https://ibn.fm/uN9tu). Indeed, the latest iteration of hurricane season is upon us, and it’s expected to be an above average year for activity, which has cities scrambling to fill public works jobs and Sustainable Green Team (OTC: SGTM) readying its crews for months of debris removal (https://ibn.fm/QFILQ). Officially, the Atlantic hurricane season, which covers the Atlantic Ocean, Gulf of Mexico and the Caribbean Sea, runs from June 1 – November 30. By definition, Elsa, the first of the year, was only a Category 1 hurricane, but it certainly demonstrated the raw power of torrential winds and rain that downed countless trees and left over 100,000 without power in its wake, including over 85,000 in New Jersey alone (https://ibn.fm/EjbBy). Sustainable Green Team, Ltd., through its subsidiaries, including National Storm Recovery LLC, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The Delaware-based company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. To understand the importance of Sustainable Green Team’s work, consider that SWEEP (Solid Waste Environmental Excellence Performance) contests that the U.S. is charting a course to run out of landfill space in the next 15 years (https://ibn.fm/DIvZS). Environmentalists also warn that uncaptured methane gas from landfills was the third biggest contributor to human-related methane emissions in the U.S. in 2018, with the equivalency to carbon dioxide emissions from 20.6 million passenger vehicles driven for one year (https://ibn.fm/esAPI). Sustainable Green Team’s solutions are rooted in sustainability and based on vertically integrated operations. In the event of a storm, SGTM’s team is deployed from a mobile command center to designated sites to strategize with national partners comprised of government agencies, prime contractors, and subcontractors. Next, its tree services division and fleet of trucks and machinery cut and gather tree debris for collection sites. From there, the processing division takes over, using the tree debris as feedstock that is turned into a variety of organic, next-generation mulch products that are subsequently sold to landscapers, installers and garden centers. In short, a downed tree isn’t used for another layer in a landfill; it’s recycled into a premium product for SGTM’s municipal, commercial, and residential customers. Better still, it helps in the efforts to prevent deforestation. The company is far removed from a typical OTC company. It has six different production facilities covering hundreds of acres in Florida and Georgia. It also has seven co-packing partners, 23 distribution centers, eight intermodal ramps, and direct contracts with CSX and Norfolk Southern to move product by rail. In 2020, SGTM acquired Ohio-based Mulch Manufacturing, widening its national footprint and adding contracts for bagged mulch with big box stores to its revenue stream. To that point, SGTM has parlayed it environmentally friendly processes into growing sales. The Company reported record revenue of $9.29 million, $1.4 million in gross profit and $41.48 million in total assets for the quarter ended April 30, 2021. No one likes to hear about a hurricane or the see the devastation one leaves behind. Unfortunately, it makes for good news reports for a few days, but then the cameras disappear, and communities are left to pick up the pieces. Thankfully, a company like SGTM is there with the complete infrastructure to assist in the eco-friendly manner to see that the environmental damage doesn’t have to be any more than it already is. For more information on Sustainable Green Team Management, visit www.CentralFloridaArborcare.com. NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• MINDCURE’s proprietary digital therapeutics technology platform creates a high barrier to entry for any potential competitors
• The company maintains active partnerships with growing firms in AI, technology, and mental health
• MINDCURE’s world-class scientific discovery team has decades of combined experience in researching and commercializing pharmaceutical grade drugs
• The company has demonstrated a clear path to near-term revenues and boasts a strong financial position

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”) is a diversified life sciences company at the forefront of the mental health industry. The company is currently developing digital therapeutics and researching psychedelic compounds, while innovating and commercializing new ways to promote healing and improve mental health. MINDCURE’s research and digital therapeutics technology supports access to safe, science-based, evidence-backed psychedelic-assisted therapies globally. With hundreds of millions of people suffering from mental illnesses worldwide and an estimated $1 trillion in lost productivity per year, psychedelics offer promising alternatives for healing. This medical need has been amplified by the COVID-19 pandemic. According to the Centers for Disease Control and Prevention, 40 percent of U.S. adults reported struggling with substance abuse or mental health issues during the pandemic. MINDCURE is uniquely positioned to address these medical needs. By concentrating on both technology and research, the company is focusing on near-term revenue generation, targeting a longer-term, blue sky horizon and hedging against regulatory unknowns with a scalable, adaptive model. MINDCURE’s software-as-a-service (SaaS) platform, iSTRYM, scales globally and services every psychedelic medicine without the capital-intensive drag of clinic scale-out costs. The company plans to first enter the market for psychedelic-assisted psychotherapy, then to move into the larger fields of technologically undisrupted psychotherapy and psychiatry. Technology Digital therapeutics include health interventions delivered through a smart device to induce a behavioral change in the patient. The global market is focused on simplifying behavioral change and empowering consumers to take charge of their own health. iSTRYM is the company’s AI-driven software platform that enables personalized and quantified outcomes in psychedelic therapy. The SaaS platform modernizes care, taking it from manual to digital and bringing better treatment outcomes for patients and therapists while lowering costs for insurers. iSTRYM offers clinicians direct access to global, science-backed, evidence-based protocols, integration plans, insights into client journeys, and real-time assessments for personalized care. Patients access the platform on their smart devices, enjoying transparency into their wellness journeys, personalized care resources, and optimized relationships with their practitioners. The minimal viable product (“MVP”) of the software is being launched in Q3 2021. MINDCURE targets a Q1-Q2 2022 commercial product launch. Research In June 2021, the company announced it had completed the first stage of manufacturing pharmaceutical-grade synthetic ibogaine to be used in clinical research. In July, MINDCURE announced it had filed U.S. Provisional Patent applications for the company’s first full synthetic routes to create ibogaine. The company’s pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug. The company is also actively researching ibogaine as a potential treatment for Traumatic Brain Injury and related conditions. Preliminary data show the drug may also have promise as a treatment for neuropathic pain and migraines. In addition, research indicates ibogaine may help repair and rewire the brain’s neural pathways, making it potentially useful in the treatment of addictions. Market Outlook MINDCURE actively develops technology, conducts research, and distributes products in several market spaces. The global market for digital therapeutics is projected to grow to $6.9 billion by 2025, from an estimated $2.1 billion in 2020. In North American alone, the market is forecast to reach $5 billion by 2025. The market for treatment of drug, alcohol and other addictions is estimated to be worth $38.2 billion in 2021, with a forecast CAGR of 5.2 percent for the next several years. The global market for the treatment of neuropathic pain is forecast to account for $9 billion by 2027, while drug treatment for migraines is expected to have a value of $2.1 billion by 2025. Management Team Kelsey Ramsden is President and CEO of MINDCURE. She has 15 years of experience founding, scaling, and operating innovative companies across Canada and the Caribbean. She has built multiple eight-figure businesses and twice been named Canada’s Top Female Entrepreneur. She holds a seat on the Entrepreneurship Council for the University of Western Ontario, where she is also a faculty member. She has an MBA from the Richard Ivey School of Business at the University of Western Ontario. Dr. Joel Raskin is the Chief Medical Officer at MINDCURE. He is a psychiatrist and academic with 20 years international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch and commercialization with Eli Lilly & Co., where, as Senior Director, he led the medical affairs team for Alzheimer’s disease diagnostics and therapeutics. He earned his medical degree from the University of Toronto and is a Fellow of the Royal College of Physicians and Surgeons of Canada in Psychiatry. Tarik Lebbadi is the COO at MINDCURE. He has more than 13 years of international operational experience. Before joining the company, he led the medical division of Johnson & Johnson in Morocco. He holds a BA in mathematics and computer science from Ripon College and an MBA from IESE Business School in Barcelona, Spain. Geoff Belair is the CTO at MINDCURE. He has 30 years of experience working in highly regulated industries, including fintech and banking. He was the senior architect and creator of the Integration Services Team at banking solutions company Fincentric Corporation. Before joining MINDCURE he was Vice President of Information Technology at Westland Insurance. Michael Wolfe, CPA CA, is MINDCURE’s CFO. He has 30 years of experience in finance, accounting, private equity, and business valuation. He was previously CFO of Baylin Technologies Inc., as well as CFO of several mid-market Canadian companies, including Masstech Group Inc. He was General Partner at VenGrowth Capital Partners Inc. He holds an MBA from McMaster University and a BA in business and economics from the University of Western Ontario. Daniel Herrera is Vice President of Growth & Strategic Partnerships at MINDCURE. He is a former pharmaceutical executive with extensive experience in highly regulated industries. He is experienced with medical affairs, product development and product licensing, negotiations with public and private payers, GPOs, and pharmacy buyers, as well as strategic partnerships resulting in high-value M&A transactions. He is a graduate of McGill University and the University of Montreal and holds an MBA from the John Molson School of Business at Concordia University. For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

• Company receives millions in funding from RB Capital Partners
• Funding provided on growth-friendly terms on an important piece of the financial foundation necessary to actualize company potential
• ISWH well positioned to execute on its bottom-line revenue goals

ISW Holdings (OTC: ISWH), a global brand management holdings company with commercial operations in telehealth and renewable energy cryptocurrency mining, has received $8 million in funding, which the company will use to develop its cryptocurrency mining and telehealth operations. The funding came from California-based RB Capital Partners Inc. “ISW Holdings has built a model with robust growth potential, and we’re excited that RB Capital has seen around that corner and was willing to provide growth-friendly terms on an important piece of the financial foundation necessary to actualize that potential,” said Alonzo Pierce, ISW Holdings president and chairman. “Given the timing of our agreement in Georgia and recent geopolitical shifts in the global cryptocurrency mining landscape, we are positioned very well at this point, and we look forward to a number of significant developments over coming weeks.” RB Capital Partners provided the funding as a premium-to-market convertible note that can only convert at a premium ($1.50 per share) to the stock’s current price (~$0.41 per share); the agreement stipulates that the conversion can only be made after 12 months. ISWH announced that RB Capital also provided for additional funding — potentially up to $12 million — offered along the same terms and to be used for additional exploration and development investment. “We are excited to be a part of ISWH’s growth trajectory and agree the company is now very well positioned to execute on its bottom-line revenue goals,” stated RB Capital Partners owner Brett Rosen. “The elimination of harmful toxic debt, coupled with the Georgia deal, put ISWH on the road to a Nasdaq uplist.” In addition to the actual funding, conditions of the funding stipulate that any capital acquired through the arrangement will be used for further development, including the infrastructure necessary to strengthen and expand cryptocurrency mining operations at ISWH’s new mining facility in Georgia, including the assembly and outfitting of additional POD5 mining pods. The funds can also be used for value-adding strategic investments, such as technology, resources and personnel capable of maximizing the efficiency of ISWH’s operations. ISW Holdings is a diversified portfolio company comprised of essential business lines that serve consumer product demands. The company’s expertise lies in strategic brand development and early growth facilitation, as well as brand identity through its proprietary procurement process. Together with its partners, ISWH seeks to provide a structure that meets large scalability demands and anticipated marketplace needs. The company meets those needs through a variety of strategic innovative processes. ISW Holdings is creating and managing brands across a spectrum of disruptive industries. It maneuvers its proprietary companies through critical stages of market development, which includes conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency. For more information, visit the company’s website at www.ISWHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH